CA2099367A1 - Synthetic peptides corresponding to portions of hiv-2 virus and methods of using in an improved assay - Google Patents
Synthetic peptides corresponding to portions of hiv-2 virus and methods of using in an improved assayInfo
- Publication number
- CA2099367A1 CA2099367A1 CA 2099367 CA2099367A CA2099367A1 CA 2099367 A1 CA2099367 A1 CA 2099367A1 CA 2099367 CA2099367 CA 2099367 CA 2099367 A CA2099367 A CA 2099367A CA 2099367 A1 CA2099367 A1 CA 2099367A1
- Authority
- CA
- Canada
- Prior art keywords
- peptide
- hiv
- antibodies
- sample
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- AIDS & HIV (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to synthetic peptides of HIV-2 and method to use the synthetic peptides in an improved im-munoassay for antibodies to HIV-2. The antigenic peptide of formula (Sequece Id. No. 1 or 2), the improvement involving adding Lysine substantially adjacent to the N or C terminus of the peptide and adding a glycine between Lysine and Aspartic acid if Ly-sine is added to the N-terminus of the antigenic peptide.
Description
W093/09252 2 0 ~ ~ 3 6 7 PCT/US92/09376 S~ C PE~DES C~ ~ TO P~IONS OF HIV-2 VIRUS
A~D) MEI~S 0~? USI:NG IN AN IMPROVf~D ASSAY
BACK5ROUND OF THE INVENTIO~
FIELD OF THE INVE~$IO~
The present invention relates to synthetic peptides and method to use these synthetic peptides in an improved immunoassay for antibodies to HIV-2.
A~D) MEI~S 0~? USI:NG IN AN IMPROVf~D ASSAY
BACK5ROUND OF THE INVENTIO~
FIELD OF THE INVE~$IO~
The present invention relates to synthetic peptides and method to use these synthetic peptides in an improved immunoassay for antibodies to HIV-2.
2. DescriDtion of the Prior Art HIV-2 is a ~irus related to HIV-l. Guyader et al., Nature 326: 662-669 (1987). The complete nucleotide sequence of HIV-2 shows a genetic sequence homology with HIV-l of 42% Id. However, studies have showed that patients with HIV-2 infection were not identified by serologic test which detect HIV-l. Certain HIV-2 antigens have been indentified as being recognized by antibodies in the sera of patients infected by HIV-2 infection. These antigens may be produced either recombinantly or synthetically. See e.g. Vahlne et al., U.S. Patent No. 4,812,556. In the '556 patent, Vahlne disclosed the amino acid sequence of certain antigenic peptides. These antigenic peptide sequences (Seq. Id. No:l) (Seq. Id. No:2) can have at its N-terminus either a H of the amino terminal NH2 group of the peptide or an additional amino acid bonded to the amino terminal NH2 group of the peptide, the additional amino acid being ~elected to facilitate coupling of the peptide to a carrier protein and at C-terminus either a OH or NH2.
Although a peptide may by its self be antigenic, in coupling the peptide to various solid phases the antigenicity may be effected. This change in W093/09252 2 0 9 9 3 6 7 -2- PCT/~S92/093/6 antigenicity may result in a solid phase that it not useful for conducting an immunoassay. In conducting an immunoassay the ability of the solid phase immunoreactant to detect HIV-2 antibodies in low concentrations is required, as these antibodies may exist in low concentration in the bodily fluid.
SUMMARY OF THE PRESENT INVENTION
The present invention relates to certain synthetic peptides corresponding to a portion of the glyco-protein gp-41 encoded by HIV-2 env gene, having the basic seguence disclosed by Vahlne et al. The improvement discovered by the inventors involves adding a Lysine substantially adjacent to either terminus of the peptide for coupling on to the solid phase and by adding a Glycine between the added Lysine and -Aspartic acid of the Vahlne et al. peptide, if Lysine is added to the N-terminus of the peptide. Surprisingly, this peptide modified for handling convenience showed improved ~ensitivity in an immunoassay.
In particular this invention relates to an antigenic peptide of the formula: (Sequence Id. No:l) wherein the improvement involves adding a Lysine substantially adjacent to either terminus of said peptide and adding a Glycine between the added Lysine and Aspartic acid, if Lysine is added to the N-terminus.
Additionally, this invention relates to an antigenic peptide of the formula: (Sequence Id. No:2) wherein the improvement involves adding a Lysine substantially adjacent to either terminus of said peptide and adding a Glycine between the added Lysine and Aspartic acid if Lysine is added to the N-terminus.
W O 93/09252 2 0 ~ ~ 3 ~ ~ PC~r/~'S92/09376 More specifically, the invention can be further defined as peptides having: a sequence of 26 amino acids (Sequence Id. No:3) 27 amino acids having (Sequence Id. No:4) as described in the sequence listing: 25 ~mino acids (Sequence Id. No:5): 26 ~mino acids (Seguence Id. No:6).
These peptides can be used for detecting antibodies to HIV-2 in a sample. The method involves contacting the sample with the peptide under conditions such that an immunological complex will form between the peptide and antibodies to HIV-2 present in the sample, if such antibodies are present in the sample, and measuring the formation, if any of the immunological complex to determine the presence of antibodies to HIV-2 in the sample DETAILED DESCRIPTION OF THE INVENTION
The present invention provides improved peptides corresponding to a region of the transmembrane glyco-protein gp-41 of HIV-2 which has been synthesized and tested for immunoreactivity to HIV-2 positive serum samples as shown by Vahlne et al., (U.S. Patent No.
4,812,556 incorporated by reference). The Vahlne et al. peptide has the following amino acid sequence:
(Seq. Id. No:l) (Seg. ld. No:2) can have at its N-terminus either a H of the Amino terminal NX2 group of the peptide or ~n additional amino acid bonded to the ~mino terminal NH2 group of the peptide, the additional amino acid being selected to facilitate coupling of the peptide to a carrier protein and at C-terminus either a OH or NH2.
The inventor's observed that the presence of Lysine in the peptide facilitates its covalent coupling to a solid surface. Consequently, the inventors extended W093/09252 2 0 ~ 9 3 ~ ~ PCT/~iS92/09376 the Vahlne et al. peptide by addition of Lysine.
Lysine can be incorporated at either end of the peptide for covalent coupling to the solid phase. The Lysine is positioned to be substantially adjacent to either terminus. The phrase substantially adjacent means within one or two amino acids of the terminus.
In addition Glycine was added between Lysine and Aspartic acid of the Vahlne et al. peptide. Glycine was added to: l) act as a spacer for better orientation of the peptide on the particles; and 2) to prevent the interact~ between -COOH group of Asp and the NH2 group of Lysine. Thus, the modified peptides may have the amino acid sequences as shown in (Sequence Id. Nos:3-6) Peptides were synthesized in the amide form on a Milligen-Biosearch 9600 model peptide synthesizer using fluorenylmethoxy carbonyl (FMOC) amino protection scheme and 1-3 diisopropyl carbodiimide coupling chemistry. The amide form of the seguence was adopted because it could be expected to more closely mimic the biologically active analogue than the free acid form.
Activated amino acids were coupled to a 2,4- dimethoxy benzhydrylamine resin. Peptide synthesis was monitored by ninhydrin analysis for all amino acids except proline for which an Isatin test was performed. The synthesized peptide was cleaved from the resin by ~eagent R, which comprises trifluoroacetic acid, thioanisole, ethanedithiol and anisol in a volumetric ratio of 90:5:3:2.
Peptides cleaved from resins were purified by high performance liquid chromatography (HPLC), and characterized by Porton Pl 20 90 E Integrated Micro Sequencing system to confirm the correct sequence.
Purity was ascertained by HPLC on a reverse phase W O 93t09252 PC~r/~'S92J09376 _52 ~ i9 .~ ~3 ~ ~
column using a linear gradient ((A) 0.1 trifluoroacetic acid in H20, (B)0.1% trifluoroacetic acid in CH3CN) of 5% to 60% (B) in 45 minutes. Absorbance was followed at 230 nm. The peptides made by this process have the amino acid sequence as shown in (Sequence Id. No:3).
These peptides were covalently coupled to carboxyl functionalized magnetic particles according to the following procedure: 1 ml of 2.5% weight/volume approximately 5 ~m paramagnetic particles were separated on a magnetic separator in a 5 ml size disposable sterile cryogenic vial (corning, cat #25708). The supernatant was removed and the particles resuspended with l ml of 70% ethanol for 10 minutes.
The particles were then separated as before and superna~ant was removed. The particles were resuspended in 1 ml of 0.1 M phosphate buffer, pH 5.5.
The particles were separated as before and supernatant was removed. ~urther washing procedure with phosphate buffer was repeated twice as before and supernatant removed.
To the slurry of particles was added 6 mg of Sulfo-N-Hydroxy Succinimide and 7 mg of 1-Ethyl-3-(Dimethylaminopropyl) carbodiimide hydrochloride. The particles resuspended and left at room temperature for 5 minutes with occasional shAking. To the activated particles was added 125 ul solution of HIV-2 peptide (lmg/ml in 0.1 M phosphate buffer, pH 7.3) followed by the addition of 875 ul of 0.1 H phosphate ~uffer, pH 7.3. The particles were mixed thoroughly and then tumbled for 12-15 hours at room temperature.
The covalently coupled peptide particles were then separated on a magnetic separator. Supernatant was removed and the particles were resuspendet in isotonic W093/09252 2 0 9 3 3 ~ ~ PCT/~ISg2/09376 buffered saline with 0.05% Tween 20 detergent. The particles were further separated and resuspended three times in isotonic buffered ~aline. The coated particles were then resuspended in isotonic buffered saline at final particles concentration of 0.2~% weight to volume. It should be noted that the C-terminus can be comprised of either amide or acid groups depending on the desired end use.
~ eptide were also passively coated onto paramagnetic microparticles according to the following procedure: 1 ml of 2.5% of weight/volume approximately 5 ~m paramagnetic particles were separated on a magnetic separator in a 5 ml si2e disposable sterile cryogenic vial (corning; cat #25708). The supernatant was removed and the particles resuspended with 1 ml of 70% ethanol for 10 minutes. The particles were then separated as before and supernatant was removed. The particles were resuspended in ~ ml of 0.1 M CHES buffer (2-(N-Cyclohexylamino) ethansulfonic acid) at pH 9.3.
The particles were separated as before and supernatant was removed. Further, washing procedure with CHES
buffer was repeated twice as before and supernatant re~oved.
To the slurry of particles was added 875 ul of O.lM
CHES buffer And 125 ul of peptide solution (1 mg/ml in O.lM CHES buffer). The particles were resuspended and then tumbled for 18 hours at room temperature.
The passively adsorbed peptide particles were then separated on a magnetic separator, supernatant removed and particles resuspended in isotonic buffered saline with 0.05% Tween 20 detergent. The particle were further separated and resuspended three times in isotonic buffered saline. The coated particles are then resuspended in isotonic buffered saline at final particle concentration of 0.2S% weight to volume.
W093/09252 2 ~ 9 9 3 SJ 7 PCT/~ISg2/09376 A paramagnetic particle assay using particles coated with peptide prepared as previously described was performed as follows: Human serum or plasma was diluted 1:100 in well buffer (20% Neonate Calf Serum, 1.06 M Sodium Chloride, 0.03 M Tris-HCL, pH 7.4, 0.018 M Phosphate buffer, pH 7.4 + or - 0.3, 0.09% Sotium Azide, and 1.01% NP-40).
50 ~1 of the diluted sample was added to each well of a Pandex black microtiter plate. Samples were tested in replicates of at least 2. Paramagnetic particles, coated with peptides as describe in example 1 or 2, were added to each well (20 ~1). The plate was then placed at 42C for 30 minutes.
Upon completion of the incubation, the particles in the wells were washed with 100 ~1 phosphate buffered saline and Tween-20 (2.06 g sodium phosphate dibasic, 0.318 g sodium phosphate monobasic 0.5 ml Tween-20, 8.76 g sodium chloride, and 1.0 g sodium azide per liter; pH 7.4). During the wash steps, the paramagnetic particles were held in the microtiter plate well via a magnetic field applied to the bottom of the plate. Particles were washed in this manner six times.
Particles in each well were resuspended in 30 ~1 of particles resuspension buffer (4.346 g sodium phosphate dibasic, 0.524 g sodium phosphate monobasic, 8.76 g sodium chloride, and 1 g sodium azide per liter;
pH 7.4) 20 ~1 of goat antihuman IgG (H+L) conjugated ~-Galactosidase (conjugate) and diluted 1:2000 in conjugate dilution buffer (0.1 M Tris-HCL pH 7.5, 0.5 M
sodium chloride, 5% glycerol, 5.25 mM magnesium chloride, 0.1% sodium azide and 20% neonate calf sera W093t09252 PCT/~'S92/09376 209~ 367 pH 7.5 ~ or - 0.3) was then added to the wells. After incubation with conjugate for 15 minutes at 42C the S particles in the wells were washed six times with phosphate buffer saline and $ween-20 as described above to remove essentially all of the unbound conjugate.
The Iween-20 in the wash solution enhanced the washing process and removed non specifically bound conjugate.
Finally, 50 ~l of a substrate solution of 4-methyl-umbelliferyl-~-D-galactoside (MUG) was added to each well (0.178 MUG, 3.58 g tricine, 5.1 ml dimethyl sulfoxide, 30 ml methyl alcohol, 0.2 g sodium azide, 0.5 ml Tween-20, per liter, pH 8.5). The presence of ~-galactosidase (ie: conjugate) in the wells triggered the cleavage of MUG to generate a fluorescent coumarin product. This reagent and conjugate were used as a sensitive detection system.
Fluorescence (excitation wavelengt~ 400 nm/e~mision wavelength 450 nm) was measured at two time intervals (i.e. 2 and 14 minutes) post MUG addition. The difference between the two values was a kinetic measurement of fluorescent product generation and is a direct measurement of conjugate and human IgG/IgM bound to the particles. Fluorescent values were converted to nM coumarin values using vArious concentrations of coumarin itself and its resultant fluorescence to establish a standard curve.
W093/09252 2 ~ 9 ~ 3 ~ 7 PcT/~'S92/09376 TO PARTICLES IN HIV ASSAY*
TEST SAMPTFS DILUTIO~ ASSAY SIG~AL**
UNMODIFIED MODIFIED
10 HIV-2 POS. 1:1600 2187 5000 1:3200 1099 2799 1:6400 563 1482 HIV-2 POS. 1:1600 1857 3009 1:3200 880 1447 1:6400 408 629 HIV-1 POS. 1:100 85 65 20 NEG.CONTROL. 1:100 go 83 * Assay conditions were 0.05% particles suspension, Goat anti Human IgG-B Galactosidase conjugate.
** Assay ~ignal is in fluorescent units.
.
~, ,0 ..
'D
WO 93/09252 2 ~ 7 PCr/l_'S92/09376 EVALUATION OF l'WO IV-2 PEPTIDES PASSIVELY ADSORBED
ON PARTICLES IN ~IV ASSAY~
TEST SAMPLES DII.UIIONASSAY SIG~AL~*
UNMODIFIED MODIFIED
HIV-2 POS. 1: 1600 1210 2307 1: 3200 570 1074 1: 6400 242 485 HIV-2 POS . 1: 1600 959 2580 1:3200 396 1242 1: 6400 i98 598 NEG.CON'rROL. 1:100 23 38 ~ Assay conditions were 0.05% particles suspension, Goat anti Human IgG-B Galactosidase conjugate.
*~ Assay signal is in fluorescent units.
The modified peptide, passively as well as covalently coupled on magnetic particles, show significantly better sensitivity compared to unmodified peptide coated onto particles under identical coating and test conditions. This better sensitivity would allow the detection of HlV-2 antibody in lower concentrations in the patent sample.
Although the invention has been described primarily in connection with special and preferred embodiments, it will be understood that it is capable of modification without departing from the scope of the invention. The following claims are intended to cover W093/09252 2 0 9 ~9 3 6 7 PcT/~ls92/o9376 all variations, uses, or adaptations of the invention, following, in general, the principles thereof and including such departures from the present disclosure as come within known or customary practice in the field to which the invention pertains, or as are obvious to persons skilled in the field.
wo 93/09252 2 ~ 9 ~ 3 ~ ~ -12- PCr/~Ss2tos376 SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLlCANT: Shah, Dinesh O
Schneider, Andrcw (ii) TITLE OF INVENTION: Synthetic Peptides Collca~onding to a Portion of HIV-2 Virus and Method To U~e The Same in an Improved Immunoassay (iii) NUMBER OF SEQUENCES: 6 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Ba~ter Diagnostics Inc.
(B) STREET: One Ba~.ter Parh~ay, DF2-2E
(C) CITY: Deerfield tD) STATE: Illinois (E) COUNTRY: usa P: 600lS
(v) COMPUIER READABLE FORM:
(A) ~EDIU~ TYPE: Floppy dislc (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTE~f: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (vi) CI~ENr APPLICATION DATA:
(A) APPLICATION NUMBER: US
(B) FILING DATE:
(C) CLASSIFICAnON:
(~iii) Al~ORNEY/AGENT INFORMATION:
(A) NA~E: Barta, Kcnt (B) REGlSTRATlON NUMBER: 29,042 (C) REFERENCE/DOCKEI NU~ER: 91 183A
(i~) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 708/948-3308 wo 93/092~
- ~ ~ 9 3 3 G 7 Pcr/~'S92/09376 (2) INFORMATION FOR SEQ ~D NO:l:
(i) SEQUENCE CHARAClERISTlCS:
(A) LENGTH: 24 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: un~nown (D) TOPOLOGY: un~cnown (ii) MOLECULE TYPE: peptide (~i) SEQUENCE DESCRIPTION: SEQ ID NO:l:
Asp Gln Ala Arg Leu Asn Ser Trp Gly Cys Ala Phe Arg Gln Val Cys 5 l0 15 His Thr Thr Val Pro Trp Val Asn (2) INFORMAnON FOR SEQ ID NO:2:
(i) SEQUENCE CHARAC~ERISTICS:
(A) LENGn~: 25 arnino acids (B) TYPE: arnino acid (C) STRANDEDNESS: unlcnown (D) TOPOLOGY: unlcnown (ii) MOLECULE TYPE: pep~de (~i) SEQUENCE DESCRIPTION: SEQ rD NO:2:
Asp Gln Ala Arg Leu Asn Ser T~p Gly Cys Ala Phe Arg Gln Val Cys S l0 lS
His Thr Thr Val Pro Tlp Val Asn Cys W093/09252 2a~93~7 PCr/~Ss2/os376 (2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGn~: 26 unino acids (B) TYPE: arnino acid (C) S~RANDEDNESS: unknown (D) TOPOLOGY: un~nown (ii) ~OLECULE TYPE: peptide (~i) SEQUENCE DESCRlPTION: SEQ ID NO:3:
Lys Gly Asp Gln Ala Arg Leu Asn Scr Trp Gly Cys Ala Phe Arg Gly 5 l0 15 Val Cys His Thr Thr Val Pro Trp Val Asn (2) ~FORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARAC-l~RISTICS:
(A) LENGTH: 27 anuno acids (B) TYPE: amino acid (C) STRANDEI)NESS: unlcnown (D) TOPOLOGY: un~cnown (ii) MOLECULE TYPE: peptidc (~i) SEQUENCE DESCRI~TION: SEQ ID NO:4:
Lys Gly Asp Gln Ala Arg Leu Asn Scr Trp Gly Cys Ala Phe Arg Gly S l0 15 Val Cys His Thr Thr Val Pro Trp Val Asn Cys wo 93/09252 - 15 - 2 0 ~ ~ 3 6 7PCr/l~S92/os376 (2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACrERlSTICS:
(A) LENGTH: 25 a nino acids (B) TYPE: arnino acid (C) STRANDEDNESS: unlcnown (D) TOPOLOGY: unlcnown (ii) MOLECULE TYPE: pcptidc (~i) SEQUENCE DESCRlPTlON: SEQ ID NO:S:
Asp Gln Ala Arg Leu Asn Scr Trp Gly Cys Ala Phe Arg Gln Val Cys S l0 15 His Thr Thr Val Pro Trp Val Asn Lys (2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACl~RISTICS:
(A) LENGnH: 26 amino acits (B) TYPE: amino acid (C) STRANDEDNESS: un~cnown (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: pcp~dc (~i) SEQUENCE DESCRIPTION: SEQ ~I) NO:6:
Asp Gln Ala Arg Lcu Asn Scr Trp Gly Cys Ala Phc Arg Gln Val Cys S l0 15 His Thr Thr Val Pro Trp Val Asn Cys Lys
Although a peptide may by its self be antigenic, in coupling the peptide to various solid phases the antigenicity may be effected. This change in W093/09252 2 0 9 9 3 6 7 -2- PCT/~S92/093/6 antigenicity may result in a solid phase that it not useful for conducting an immunoassay. In conducting an immunoassay the ability of the solid phase immunoreactant to detect HIV-2 antibodies in low concentrations is required, as these antibodies may exist in low concentration in the bodily fluid.
SUMMARY OF THE PRESENT INVENTION
The present invention relates to certain synthetic peptides corresponding to a portion of the glyco-protein gp-41 encoded by HIV-2 env gene, having the basic seguence disclosed by Vahlne et al. The improvement discovered by the inventors involves adding a Lysine substantially adjacent to either terminus of the peptide for coupling on to the solid phase and by adding a Glycine between the added Lysine and -Aspartic acid of the Vahlne et al. peptide, if Lysine is added to the N-terminus of the peptide. Surprisingly, this peptide modified for handling convenience showed improved ~ensitivity in an immunoassay.
In particular this invention relates to an antigenic peptide of the formula: (Sequence Id. No:l) wherein the improvement involves adding a Lysine substantially adjacent to either terminus of said peptide and adding a Glycine between the added Lysine and Aspartic acid, if Lysine is added to the N-terminus.
Additionally, this invention relates to an antigenic peptide of the formula: (Sequence Id. No:2) wherein the improvement involves adding a Lysine substantially adjacent to either terminus of said peptide and adding a Glycine between the added Lysine and Aspartic acid if Lysine is added to the N-terminus.
W O 93/09252 2 0 ~ ~ 3 ~ ~ PC~r/~'S92/09376 More specifically, the invention can be further defined as peptides having: a sequence of 26 amino acids (Sequence Id. No:3) 27 amino acids having (Sequence Id. No:4) as described in the sequence listing: 25 ~mino acids (Sequence Id. No:5): 26 ~mino acids (Seguence Id. No:6).
These peptides can be used for detecting antibodies to HIV-2 in a sample. The method involves contacting the sample with the peptide under conditions such that an immunological complex will form between the peptide and antibodies to HIV-2 present in the sample, if such antibodies are present in the sample, and measuring the formation, if any of the immunological complex to determine the presence of antibodies to HIV-2 in the sample DETAILED DESCRIPTION OF THE INVENTION
The present invention provides improved peptides corresponding to a region of the transmembrane glyco-protein gp-41 of HIV-2 which has been synthesized and tested for immunoreactivity to HIV-2 positive serum samples as shown by Vahlne et al., (U.S. Patent No.
4,812,556 incorporated by reference). The Vahlne et al. peptide has the following amino acid sequence:
(Seq. Id. No:l) (Seg. ld. No:2) can have at its N-terminus either a H of the Amino terminal NX2 group of the peptide or ~n additional amino acid bonded to the ~mino terminal NH2 group of the peptide, the additional amino acid being selected to facilitate coupling of the peptide to a carrier protein and at C-terminus either a OH or NH2.
The inventor's observed that the presence of Lysine in the peptide facilitates its covalent coupling to a solid surface. Consequently, the inventors extended W093/09252 2 0 ~ 9 3 ~ ~ PCT/~iS92/09376 the Vahlne et al. peptide by addition of Lysine.
Lysine can be incorporated at either end of the peptide for covalent coupling to the solid phase. The Lysine is positioned to be substantially adjacent to either terminus. The phrase substantially adjacent means within one or two amino acids of the terminus.
In addition Glycine was added between Lysine and Aspartic acid of the Vahlne et al. peptide. Glycine was added to: l) act as a spacer for better orientation of the peptide on the particles; and 2) to prevent the interact~ between -COOH group of Asp and the NH2 group of Lysine. Thus, the modified peptides may have the amino acid sequences as shown in (Sequence Id. Nos:3-6) Peptides were synthesized in the amide form on a Milligen-Biosearch 9600 model peptide synthesizer using fluorenylmethoxy carbonyl (FMOC) amino protection scheme and 1-3 diisopropyl carbodiimide coupling chemistry. The amide form of the seguence was adopted because it could be expected to more closely mimic the biologically active analogue than the free acid form.
Activated amino acids were coupled to a 2,4- dimethoxy benzhydrylamine resin. Peptide synthesis was monitored by ninhydrin analysis for all amino acids except proline for which an Isatin test was performed. The synthesized peptide was cleaved from the resin by ~eagent R, which comprises trifluoroacetic acid, thioanisole, ethanedithiol and anisol in a volumetric ratio of 90:5:3:2.
Peptides cleaved from resins were purified by high performance liquid chromatography (HPLC), and characterized by Porton Pl 20 90 E Integrated Micro Sequencing system to confirm the correct sequence.
Purity was ascertained by HPLC on a reverse phase W O 93t09252 PC~r/~'S92J09376 _52 ~ i9 .~ ~3 ~ ~
column using a linear gradient ((A) 0.1 trifluoroacetic acid in H20, (B)0.1% trifluoroacetic acid in CH3CN) of 5% to 60% (B) in 45 minutes. Absorbance was followed at 230 nm. The peptides made by this process have the amino acid sequence as shown in (Sequence Id. No:3).
These peptides were covalently coupled to carboxyl functionalized magnetic particles according to the following procedure: 1 ml of 2.5% weight/volume approximately 5 ~m paramagnetic particles were separated on a magnetic separator in a 5 ml size disposable sterile cryogenic vial (corning, cat #25708). The supernatant was removed and the particles resuspended with l ml of 70% ethanol for 10 minutes.
The particles were then separated as before and superna~ant was removed. The particles were resuspended in 1 ml of 0.1 M phosphate buffer, pH 5.5.
The particles were separated as before and supernatant was removed. ~urther washing procedure with phosphate buffer was repeated twice as before and supernatant removed.
To the slurry of particles was added 6 mg of Sulfo-N-Hydroxy Succinimide and 7 mg of 1-Ethyl-3-(Dimethylaminopropyl) carbodiimide hydrochloride. The particles resuspended and left at room temperature for 5 minutes with occasional shAking. To the activated particles was added 125 ul solution of HIV-2 peptide (lmg/ml in 0.1 M phosphate buffer, pH 7.3) followed by the addition of 875 ul of 0.1 H phosphate ~uffer, pH 7.3. The particles were mixed thoroughly and then tumbled for 12-15 hours at room temperature.
The covalently coupled peptide particles were then separated on a magnetic separator. Supernatant was removed and the particles were resuspendet in isotonic W093/09252 2 0 9 3 3 ~ ~ PCT/~ISg2/09376 buffered saline with 0.05% Tween 20 detergent. The particles were further separated and resuspended three times in isotonic buffered ~aline. The coated particles were then resuspended in isotonic buffered saline at final particles concentration of 0.2~% weight to volume. It should be noted that the C-terminus can be comprised of either amide or acid groups depending on the desired end use.
~ eptide were also passively coated onto paramagnetic microparticles according to the following procedure: 1 ml of 2.5% of weight/volume approximately 5 ~m paramagnetic particles were separated on a magnetic separator in a 5 ml si2e disposable sterile cryogenic vial (corning; cat #25708). The supernatant was removed and the particles resuspended with 1 ml of 70% ethanol for 10 minutes. The particles were then separated as before and supernatant was removed. The particles were resuspended in ~ ml of 0.1 M CHES buffer (2-(N-Cyclohexylamino) ethansulfonic acid) at pH 9.3.
The particles were separated as before and supernatant was removed. Further, washing procedure with CHES
buffer was repeated twice as before and supernatant re~oved.
To the slurry of particles was added 875 ul of O.lM
CHES buffer And 125 ul of peptide solution (1 mg/ml in O.lM CHES buffer). The particles were resuspended and then tumbled for 18 hours at room temperature.
The passively adsorbed peptide particles were then separated on a magnetic separator, supernatant removed and particles resuspended in isotonic buffered saline with 0.05% Tween 20 detergent. The particle were further separated and resuspended three times in isotonic buffered saline. The coated particles are then resuspended in isotonic buffered saline at final particle concentration of 0.2S% weight to volume.
W093/09252 2 ~ 9 9 3 SJ 7 PCT/~ISg2/09376 A paramagnetic particle assay using particles coated with peptide prepared as previously described was performed as follows: Human serum or plasma was diluted 1:100 in well buffer (20% Neonate Calf Serum, 1.06 M Sodium Chloride, 0.03 M Tris-HCL, pH 7.4, 0.018 M Phosphate buffer, pH 7.4 + or - 0.3, 0.09% Sotium Azide, and 1.01% NP-40).
50 ~1 of the diluted sample was added to each well of a Pandex black microtiter plate. Samples were tested in replicates of at least 2. Paramagnetic particles, coated with peptides as describe in example 1 or 2, were added to each well (20 ~1). The plate was then placed at 42C for 30 minutes.
Upon completion of the incubation, the particles in the wells were washed with 100 ~1 phosphate buffered saline and Tween-20 (2.06 g sodium phosphate dibasic, 0.318 g sodium phosphate monobasic 0.5 ml Tween-20, 8.76 g sodium chloride, and 1.0 g sodium azide per liter; pH 7.4). During the wash steps, the paramagnetic particles were held in the microtiter plate well via a magnetic field applied to the bottom of the plate. Particles were washed in this manner six times.
Particles in each well were resuspended in 30 ~1 of particles resuspension buffer (4.346 g sodium phosphate dibasic, 0.524 g sodium phosphate monobasic, 8.76 g sodium chloride, and 1 g sodium azide per liter;
pH 7.4) 20 ~1 of goat antihuman IgG (H+L) conjugated ~-Galactosidase (conjugate) and diluted 1:2000 in conjugate dilution buffer (0.1 M Tris-HCL pH 7.5, 0.5 M
sodium chloride, 5% glycerol, 5.25 mM magnesium chloride, 0.1% sodium azide and 20% neonate calf sera W093t09252 PCT/~'S92/09376 209~ 367 pH 7.5 ~ or - 0.3) was then added to the wells. After incubation with conjugate for 15 minutes at 42C the S particles in the wells were washed six times with phosphate buffer saline and $ween-20 as described above to remove essentially all of the unbound conjugate.
The Iween-20 in the wash solution enhanced the washing process and removed non specifically bound conjugate.
Finally, 50 ~l of a substrate solution of 4-methyl-umbelliferyl-~-D-galactoside (MUG) was added to each well (0.178 MUG, 3.58 g tricine, 5.1 ml dimethyl sulfoxide, 30 ml methyl alcohol, 0.2 g sodium azide, 0.5 ml Tween-20, per liter, pH 8.5). The presence of ~-galactosidase (ie: conjugate) in the wells triggered the cleavage of MUG to generate a fluorescent coumarin product. This reagent and conjugate were used as a sensitive detection system.
Fluorescence (excitation wavelengt~ 400 nm/e~mision wavelength 450 nm) was measured at two time intervals (i.e. 2 and 14 minutes) post MUG addition. The difference between the two values was a kinetic measurement of fluorescent product generation and is a direct measurement of conjugate and human IgG/IgM bound to the particles. Fluorescent values were converted to nM coumarin values using vArious concentrations of coumarin itself and its resultant fluorescence to establish a standard curve.
W093/09252 2 ~ 9 ~ 3 ~ 7 PcT/~'S92/09376 TO PARTICLES IN HIV ASSAY*
TEST SAMPTFS DILUTIO~ ASSAY SIG~AL**
UNMODIFIED MODIFIED
10 HIV-2 POS. 1:1600 2187 5000 1:3200 1099 2799 1:6400 563 1482 HIV-2 POS. 1:1600 1857 3009 1:3200 880 1447 1:6400 408 629 HIV-1 POS. 1:100 85 65 20 NEG.CONTROL. 1:100 go 83 * Assay conditions were 0.05% particles suspension, Goat anti Human IgG-B Galactosidase conjugate.
** Assay ~ignal is in fluorescent units.
.
~, ,0 ..
'D
WO 93/09252 2 ~ 7 PCr/l_'S92/09376 EVALUATION OF l'WO IV-2 PEPTIDES PASSIVELY ADSORBED
ON PARTICLES IN ~IV ASSAY~
TEST SAMPLES DII.UIIONASSAY SIG~AL~*
UNMODIFIED MODIFIED
HIV-2 POS. 1: 1600 1210 2307 1: 3200 570 1074 1: 6400 242 485 HIV-2 POS . 1: 1600 959 2580 1:3200 396 1242 1: 6400 i98 598 NEG.CON'rROL. 1:100 23 38 ~ Assay conditions were 0.05% particles suspension, Goat anti Human IgG-B Galactosidase conjugate.
*~ Assay signal is in fluorescent units.
The modified peptide, passively as well as covalently coupled on magnetic particles, show significantly better sensitivity compared to unmodified peptide coated onto particles under identical coating and test conditions. This better sensitivity would allow the detection of HlV-2 antibody in lower concentrations in the patent sample.
Although the invention has been described primarily in connection with special and preferred embodiments, it will be understood that it is capable of modification without departing from the scope of the invention. The following claims are intended to cover W093/09252 2 0 9 ~9 3 6 7 PcT/~ls92/o9376 all variations, uses, or adaptations of the invention, following, in general, the principles thereof and including such departures from the present disclosure as come within known or customary practice in the field to which the invention pertains, or as are obvious to persons skilled in the field.
wo 93/09252 2 ~ 9 ~ 3 ~ ~ -12- PCr/~Ss2tos376 SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLlCANT: Shah, Dinesh O
Schneider, Andrcw (ii) TITLE OF INVENTION: Synthetic Peptides Collca~onding to a Portion of HIV-2 Virus and Method To U~e The Same in an Improved Immunoassay (iii) NUMBER OF SEQUENCES: 6 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Ba~ter Diagnostics Inc.
(B) STREET: One Ba~.ter Parh~ay, DF2-2E
(C) CITY: Deerfield tD) STATE: Illinois (E) COUNTRY: usa P: 600lS
(v) COMPUIER READABLE FORM:
(A) ~EDIU~ TYPE: Floppy dislc (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTE~f: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (vi) CI~ENr APPLICATION DATA:
(A) APPLICATION NUMBER: US
(B) FILING DATE:
(C) CLASSIFICAnON:
(~iii) Al~ORNEY/AGENT INFORMATION:
(A) NA~E: Barta, Kcnt (B) REGlSTRATlON NUMBER: 29,042 (C) REFERENCE/DOCKEI NU~ER: 91 183A
(i~) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 708/948-3308 wo 93/092~
- ~ ~ 9 3 3 G 7 Pcr/~'S92/09376 (2) INFORMATION FOR SEQ ~D NO:l:
(i) SEQUENCE CHARAClERISTlCS:
(A) LENGTH: 24 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: un~nown (D) TOPOLOGY: un~cnown (ii) MOLECULE TYPE: peptide (~i) SEQUENCE DESCRIPTION: SEQ ID NO:l:
Asp Gln Ala Arg Leu Asn Ser Trp Gly Cys Ala Phe Arg Gln Val Cys 5 l0 15 His Thr Thr Val Pro Trp Val Asn (2) INFORMAnON FOR SEQ ID NO:2:
(i) SEQUENCE CHARAC~ERISTICS:
(A) LENGn~: 25 arnino acids (B) TYPE: arnino acid (C) STRANDEDNESS: unlcnown (D) TOPOLOGY: unlcnown (ii) MOLECULE TYPE: pep~de (~i) SEQUENCE DESCRIPTION: SEQ rD NO:2:
Asp Gln Ala Arg Leu Asn Ser T~p Gly Cys Ala Phe Arg Gln Val Cys S l0 lS
His Thr Thr Val Pro Tlp Val Asn Cys W093/09252 2a~93~7 PCr/~Ss2/os376 (2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGn~: 26 unino acids (B) TYPE: arnino acid (C) S~RANDEDNESS: unknown (D) TOPOLOGY: un~nown (ii) ~OLECULE TYPE: peptide (~i) SEQUENCE DESCRlPTION: SEQ ID NO:3:
Lys Gly Asp Gln Ala Arg Leu Asn Scr Trp Gly Cys Ala Phe Arg Gly 5 l0 15 Val Cys His Thr Thr Val Pro Trp Val Asn (2) ~FORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARAC-l~RISTICS:
(A) LENGTH: 27 anuno acids (B) TYPE: amino acid (C) STRANDEI)NESS: unlcnown (D) TOPOLOGY: un~cnown (ii) MOLECULE TYPE: peptidc (~i) SEQUENCE DESCRI~TION: SEQ ID NO:4:
Lys Gly Asp Gln Ala Arg Leu Asn Scr Trp Gly Cys Ala Phe Arg Gly S l0 15 Val Cys His Thr Thr Val Pro Trp Val Asn Cys wo 93/09252 - 15 - 2 0 ~ ~ 3 6 7PCr/l~S92/os376 (2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACrERlSTICS:
(A) LENGTH: 25 a nino acids (B) TYPE: arnino acid (C) STRANDEDNESS: unlcnown (D) TOPOLOGY: unlcnown (ii) MOLECULE TYPE: pcptidc (~i) SEQUENCE DESCRlPTlON: SEQ ID NO:S:
Asp Gln Ala Arg Leu Asn Scr Trp Gly Cys Ala Phe Arg Gln Val Cys S l0 15 His Thr Thr Val Pro Trp Val Asn Lys (2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACl~RISTICS:
(A) LENGnH: 26 amino acits (B) TYPE: amino acid (C) STRANDEDNESS: un~cnown (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: pcp~dc (~i) SEQUENCE DESCRIPTION: SEQ ~I) NO:6:
Asp Gln Ala Arg Lcu Asn Scr Trp Gly Cys Ala Phc Arg Gln Val Cys S l0 15 His Thr Thr Val Pro Trp Val Asn Cys Lys
Claims (6)
1. An antigenic peptide of the formula: (Sequence Id.
No:1) the improvement comprising:
a) adding a Lysine substantially adjacent to either terminus of said peptide;
b) adding a Glycine between said added Lysine and Aspartic acid if Lysine is added to the N-terminus ?? said antigenic peptide.
No:1) the improvement comprising:
a) adding a Lysine substantially adjacent to either terminus of said peptide;
b) adding a Glycine between said added Lysine and Aspartic acid if Lysine is added to the N-terminus ?? said antigenic peptide.
2 A method for detecting antibodies to HIV-2 in a sample comprising:
a) contacting said sample with the peptide of claim 1 under conditions such that an immunological complex will form between the peptide and antibodies to HIV-2, if such antibodies are present in the sample and b) measuring the formation, if any of the immunological complex to determine the presence of antibodies to HIV-2 in said sample.
a) contacting said sample with the peptide of claim 1 under conditions such that an immunological complex will form between the peptide and antibodies to HIV-2, if such antibodies are present in the sample and b) measuring the formation, if any of the immunological complex to determine the presence of antibodies to HIV-2 in said sample.
3. An antigenic peptide of the formula: (Sequence Id.
No:2) the improvement comprising:
a) adding a Lysine substantially adjacent to either terminus of said antigenic peptide;
b) adding a Glycine between said added Lysine if Lysine is added to the N-terminus.
No:2) the improvement comprising:
a) adding a Lysine substantially adjacent to either terminus of said antigenic peptide;
b) adding a Glycine between said added Lysine if Lysine is added to the N-terminus.
4. A method for detecting antibodies to HIV-2 in a sample comprising:
a) contacting said sample with the peptide of claim 2 under conditions such that an immunological complex will form between the peptide and antibodies to HIV-2, if such antibodies are present in the sample and b) measuring the formation, if any of the immunological complex to determine the presence of antibodies to HIV-2 in said sample.
a) contacting said sample with the peptide of claim 2 under conditions such that an immunological complex will form between the peptide and antibodies to HIV-2, if such antibodies are present in the sample and b) measuring the formation, if any of the immunological complex to determine the presence of antibodies to HIV-2 in said sample.
5. A synthetic peptide compound capable of binding to antibodies to HIV-2 consisting of a peptide selected from the group of peptides represented by the following N-terminal to C-terminal amino acid sequences:
a. Sequence Id : No 3 b. Sequence Id : No 4 b. Sequence Id : No 5 c. Sequence Id : No 6
a. Sequence Id : No 3 b. Sequence Id : No 4 b. Sequence Id : No 5 c. Sequence Id : No 6
6. A method for detecting antibodies to HIV-2 in a sample comprising:
a) contacting said sample with the peptide of claim 5 under conditions such that an immunological complex will form between the peptide and antibodies to HIV-2, if such antibodies are present in the sample and b) measuring the formation, if any of the immunological complex to determine the presence of antibodies to HIV-2 in said sample.
a) contacting said sample with the peptide of claim 5 under conditions such that an immunological complex will form between the peptide and antibodies to HIV-2, if such antibodies are present in the sample and b) measuring the formation, if any of the immunological complex to determine the presence of antibodies to HIV-2 in said sample.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78991491A | 1991-11-04 | 1991-11-04 | |
| US7/789,914 | 1991-11-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2099367A1 true CA2099367A1 (en) | 1993-05-05 |
Family
ID=25149091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2099367 Abandoned CA2099367A1 (en) | 1991-11-04 | 1992-11-04 | Synthetic peptides corresponding to portions of hiv-2 virus and methods of using in an improved assay |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0565704A4 (en) |
| JP (1) | JPH06503843A (en) |
| AU (1) | AU657590B2 (en) |
| CA (1) | CA2099367A1 (en) |
| WO (1) | WO1993009252A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08510063A (en) * | 1994-03-02 | 1996-10-22 | アボツト・ラボラトリーズ | HIV immunoassay using recombinant protein and synthetic peptide reagents |
| US5977299A (en) * | 1997-04-07 | 1999-11-02 | Dade Behring Marburg Gmbh | Activated peptides and conjugates |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5075211A (en) * | 1986-03-26 | 1991-12-24 | Genetic Systems Corporation | Synthetic antigen for the detection of AIDS-related disease |
| US4812556A (en) * | 1987-05-18 | 1989-03-14 | Virovahl | Synthetic peptide antigen for the detection of HIV-2 infection |
| GB9005829D0 (en) * | 1990-03-15 | 1990-05-09 | Proteus Biotech Ltd | Synthetic polypeptides |
-
1992
- 1992-11-04 JP JP5508647A patent/JPH06503843A/en active Pending
- 1992-11-04 CA CA 2099367 patent/CA2099367A1/en not_active Abandoned
- 1992-11-04 AU AU30598/92A patent/AU657590B2/en not_active Ceased
- 1992-11-04 WO PCT/US1992/009376 patent/WO1993009252A1/en not_active Application Discontinuation
- 1992-11-04 EP EP92924201A patent/EP0565704A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP0565704A4 (en) | 1995-10-25 |
| AU657590B2 (en) | 1995-03-16 |
| EP0565704A1 (en) | 1993-10-20 |
| WO1993009252A1 (en) | 1993-05-13 |
| AU3059892A (en) | 1993-06-07 |
| JPH06503843A (en) | 1994-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2102301C (en) | Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them | |
| JP4171508B2 (en) | Hepatitis C virus 5 and 6 | |
| JPH07503614A (en) | Mammalian expression system for HCV proteins | |
| US20060276622A1 (en) | Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them | |
| US5229491A (en) | Peptides immunochemically reactive with antibodies directed against hepatitis non-a, non-b virus | |
| CA2119013A1 (en) | Hepatitis c assay | |
| JP2666903B2 (en) | HCV peptide antigen and method for measuring HCV | |
| CA2099367A1 (en) | Synthetic peptides corresponding to portions of hiv-2 virus and methods of using in an improved assay | |
| JP2813768B2 (en) | Foot-and-mouth disease diagnostic peptide and foot-and-mouth disease diagnostic antigen containing the peptide | |
| US6709828B1 (en) | Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them | |
| EP0525910A1 (en) | Non-A, non-B peptide | |
| AU660752B2 (en) | Immunoassay using synthetic HTLV-11 peptides | |
| JP2655205B2 (en) | Assay for non-A non-B hepatitis | |
| EP0628079A1 (en) | Hepatitis c virus peptides | |
| US20020150990A1 (en) | Hepatitis C virus peptides | |
| JPH04221398A (en) | Antibody to non-a, non-b hepatitis virus and immunochemically reactive peptide | |
| DE DK et al. | HCV MOSAIK ANTIGEN ZUSAMMENSETZUNG COMPOSITION D’ANTIGENE MOSAIQUE DU VIRUS DE L’HEPATITE C (VHC) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |